Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-02-08
2005-02-08
Clardy, S. Mark (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S011400, C530S317000
Reexamination Certificate
active
06852689
ABSTRACT:
The invention provides methods for administering a therapeutically effective amount of daptomycin while minimizing skeletal muscle toxicity. The methods provide daptomycin administration at a dosing interval of 24 hours or greater. This long dosing interval minimizes skeletal muscle toxicity and allows for higher peak concentrations of daptomycin, which is related to daptomycin's efficacy. The invention also provides methods of administering lipopeptide antibiotics other than daptomycin while minimizing skeletal muscle toxicity by administering a therapeutically effective amount of the lipopeptide antibiotic at a dosage interval that does not result in muscle toxicity. The invention also provides methods of administering quinupristin/dalfopristin while minimizing skeletal muscle toxicity by administering a therapeutically effective amount of quinupristin/dalfopristin at a dosage interval that dos not result in muscle toxicity.
REFERENCES:
patent: 4482487 (1984-11-01), Abbott
patent: 4524135 (1985-06-01), Abbott
patent: 4537717 (1985-08-01), Abbott
patent: RE32310 (1986-12-01), Debono
patent: RE32311 (1986-12-01), Debono
patent: RE32333 (1987-01-01), Hamill
patent: RE32455 (1987-07-01), Hamill
patent: 4800157 (1989-01-01), Eaton
patent: 4874843 (1989-10-01), Baker
patent: 4885243 (1989-12-01), Huber
patent: 5912226 (1999-06-01), Baker
patent: 0 386 951 (1990-09-01), None
patent: WO 9822107 (1998-05-01), None
patent: WO 9930728 (1999-06-01), None
Woodworth et al., “Single-Dose Pharmacokinetics and Antibacterial Activity of Daptomycin, a New Lipopeptide Antibiotic, in Healthy Volunteers,”Antimicrobial Agents and Chemotherapy36:318-325, 1992.
Woodworth et al., “Tobramycin and Daptomycin Disposition When Co-Adminstered to Healthy Volunteers,”Journal of Antimicrobial Chemotherapy33:655-659, 1994.
Bernard et al., “Pharmacokinetics and Suction Blister Fluid Penetration of a Semisynthetic Injectable Streptogramin RP59500 (RP 57699/RP54476),”Eur. J. Clin. Microbiol. Infect. Dis.13: 768-771, 1994.
Tally et al., “Daptomycin: A Novel Agent for Gram-Positive Infections,”Exp. Opin. Invest. Drugs8:1223-1238, 1999.
Moellering et al., “The Efficacy and Safety of Quinupristin/Dalfopristin for the Treatment of Infections Caused by Vancomycin-ResistantEnterococcus faecium,” Journal of Antimicrobial Chemotherapy44: 251-261, 1999.
Richard H. Baltz, “Lipopeptide Antibiotics produced byStreptomyces roseosporusandStreptomyces fradiae,” Biotechnology of Antibiotics2d Ed., 415-435, 1997.
Boxenbaum et al., “Interspecies Pharmacokinetic Scaling, Biological Design and Neoteny,”Advances in Drug Research19: 139-196, 1990.
Caron et al., “Daptomycin or Teicoplanin in Combination with Gentamicin for Treatment of Experimental Endocarditis Due to a Highly Glycopeptide-Resistant Isolate ofEnterococcus faecium,” Antimicrobial Agents and Chemotherapy36:2611-2616, 1992.
Flandrois et al., “Early Stages of In Vitro Killing Curve of LY146032 and Vancomycin forStaphylococcus aureus,” Antimicrobial Agents and Chemotherapy32:454-457, 1998.
Freireich et al., “Quantitative Comparsion of Toxicity of Anticancer Agents in Mouse, Rat, Hamster, Dog, Monkey, and Man,”Cancer Chemotherapy Reports50: 219-244, 1966.
Garrison et al., “Suboptimal Effect of Daptomycin in the Treatment of Bacteremias,”Southern Medical Journal82: 1414-1415, 1989.
Garrison et al., “Assessment of Effects of Protein Binding or Daptomycin and Vancomycin Killing ofStaphylococcus aureusby Using an In Vitro Pharmacodynamic Model,”Antimicrobial Agents and Chemotherapy34: 1925-1931, 1990.
Gray et al., “Antibiotic-resistant enterococci,”Journal of Hospital Infection21:1-14, 1992.
Hanberger et al., “Pharmacodynamics of Daptomycin and Vancomycin onEnterococcus faecalisandStaphylococcus aureusDemonstrated by Studies of Initial Killing and Postantibiotic Effect and Infuence of Ca2+and Albumin on These Drugs,”Antimicrobial Agents and Chemotherapy35: 1710-1716, 1991.
Kaatz et al., “Daptomycin Compared with Teicoplanin and Vancomycin for Therapy of ExperimentalStaphylococcus aureusEndocarditis,”Antimicrobial Agents and Chemotherapy34: 2081-2085, 1990.
Lamp et al., “In Vitro Pharmacodynamic Effects of Concentration, pH, and Growth Phase on Serum Bactericidal Activities of Daptomycin and Vancomycin,”Antimicrobial Agents and Chemotherapy36: 2709-2714, 1992.
Lee et al., “Daptomycin versus Conventional Therapy in the Treatment of Endocarditis and Bacteremia,”Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy,A885, 1991.
Lee et al., “Effect of Protein Binding of Daptomycin on MIC and Antibacterial Activity,”Antimicrobial Agents and Chemotherapy35: 2505-2508, 1991.
Low et al., “Enterococcis: Pathogens of the 90s,”The European Journal of Surgery Suppl.573: 19-24, 1994.
Ole-Mapenay et al., “Aspects of the Pharmacokinetics of Doxycycline Given to Healthy and Pneumonic East African Dwarf Goats by Intramuscular Injection,”Veterinary Research Communications21:453-462, 1997.
Prieur et al., “Clinical Toxicologic Evaluation of Cancer Chemotherapeutic Agents: Protocols of the Laboratory of Toxicology,”Cancer Chemotherapy Reports4: 1-30, 1973.
Ramos et al., “Comparison of Daptomycin, Vancomycin, and Ampicillin-Gentamicin for Treatment of Experimental Endocarditis Caused by Penicillin-Resistant Enterococci,”Antimicrobial Agents and Chemotherapy36: 1864-1869, 1992.
Rotschafer et al., “Therapeutic Update on Glycopeptide and Lipopeptide Antiboitics,”Pharmacotherapy8:211-219, 1988.
Rybak et al., “Pharmacokinetics and Bactericidal Rates of Daptomycin and Vancomycin in Intravenous Drug Abusers Being Treated for Gram-Positive Endocarditis and Bacteremia,”Antimicrobial Agents and Chemotherapy36: 1109-1114, 1992.
Sexton et al., “The Use of Daptomycin, a Lipopeptide Antibiotic, in the Treatment of Gram Positive Infections in Man,,”Abstracts of the Interscience Conference on Antimicrobial Agents and ChemotherapyA932, 1988.
Stratton et al., “Bactericidal Activity of Deptomycin (LY146032) Compared with Those of Ciprofloxacin, Vancomycin, and Ampicillin against Enterococci as Determined by Kill-Kinetic Studies,”Antimicrobial Agents and Chemotherapy31:1014-1016, 1987.
Stratton et al., “Effect of Human Serum on the Bactericidal Activity of Daptomycin and Vancomycin Against Staphylococcal and Enterococcal Isolates as Determined by Time-Kill Kinetic Studies,”Diagnostic Microbiology and Infectious Disease13:245-252, 1990.
Tally et al., “Daptomycin: a novel agent for Gram-positive infections,”Exp. Opin. Invest Drugs8: 1223-1238, 1999.
Thompson, “Dosage Regimen Design: A Pharmacokinetic Approach,”The Journal of Clinical Pharmacology32:210-214, 1992.
Vemuri et al., “Enterococcal infections: The increasing threat of nosocomial spread and drug resistance.,”Journal of Postgraduate Medicine93: 121-128, 1993.
Voom et al., “Role of Tolerance in Treatment and Prophylaxis of ExperimentalStaphylococcus areusEndocarditis with Vancomycin, Teicoplanin, and Daptomycin,”Antimicrobial Agents and Chemotherapy38: 487-493, 1994.
Bayer, Arnold S., et al., “LY146032 Compared with Penicillin G in Experimental Aortic Valve Endocarditis Caused by Group G Streptococci,”Antimicrobial Agents and Chemotherapy32: 141-143 (1988).
Beauchamp, Denis, et al., “Effects of Daptomycin and Vancomycin on Tobramycin Nephrotoxicity in Rats,”Antimicrobial Agents and Chemotherapy34: 139-147 (1990).
Black, H.R., et al., “Preliminary Pharmacology and Pharmacokinetics of LY146032, A New Peptolipide Antibiotic,”Program and Abstracts of the 1986 Interscience Conference on Antimicrobial Agents and Chemotherapy,p. 261, Abstract 894 (1986).
Bush, Larry M., et al.,
Oleson, Jr. Frederick B.
Tally Francis P.
Choi Frank
Clardy S. Mark
Cubist Pharmaceuticals, Inc.
Douros Timothy J.
Mandelblatt Jill M. N.
LandOfFree
Methods for administration of antibiotics does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for administration of antibiotics, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for administration of antibiotics will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3493359